NCT02048488View on ClinicalTrials.gov

A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

June 30, 2018

Conditions
Solid TumorsLymphomas
Interventions
DRUG

TSR-011

Number of cycles until progression or unacceptable toxicity develops.

Trial Locations (15)

Unknown

Goodyear

Scottsdale

Los Angeles

Nashville

Norfolk

Spokane

Poznan

Warsaw

Gdansk

Olsztyn

Madrid

Santiago de Compostela

Tainan City

Taipei

London

All Listed Sponsors
lead

Tesaro, Inc.

INDUSTRY

NCT02048488 - A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | Biotech Hunter | Biotech Hunter